In this study, CCR9 abrogation was suggested to ameliorate MI-induced electrical remodeling by affecting ion current, AP, calcium homeostasis and cardiac conduction as well as gap junction, suggesting it may be a novel pharmaceutical target for the treatment of MI-induced arrhythmia. This evidence concerns the gene CCR9 and Arrhythmia.